Scinai Immunotherapeutics (SCNI) Change in Account Payables (2018 - 2024)
Scinai Immunotherapeutics' (SCNI) quarterly Change in Account Payables came in at -$54000.0 in Q4 2024, up 73.79% year-on-year from -$31072.6 in Q1 2024, and up 76.21% quarter-over-quarter from -$227000.0 in Q3 2024.
Scinai Immunotherapeutics (SCNI) Change in Account Payables (2018 - 2024) Analysis & Trends
Scinai Immunotherapeutics has disclosed Change in Account Payables across 7 years of filings, most recently posting -$54000.0 for Q4 2024.
- Change in Account Payables for Q4 2024 came in at -$54000.0, up 73.79% year-over-year; the trailing twelve-month figure through Dec 2024 was -$156000.0 (up 54.25% YoY), and the FY2025 annual result was $31000.0, up 119.87% from the prior year.
- Change in Account Payables came in at -$54000.0 for Q4 2024 at Scinai Immunotherapeutics, up from -$227000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $4.1 million in Q3 2020 to a low of -$6.3 million in Q4 2020.
- The 5-year median for Change in Account Payables is $65000.0 (2021), against an average of -$64894.7.
- Peak annual rise in Change in Account Payables reached 696.2% in 2023, while the deepest fall reached 241.1% in 2023.
- Scinai Immunotherapeutics' Change in Account Payables stood at -$6.3 million in 2020, then jumped by 93.0% to -$444000.0 in 2021, then soared by 132.88% to $146000.0 in 2022, then slumped by 241.1% to -$206000.0 in 2023, then jumped by 73.79% to -$54000.0 in 2024.
- The last three Change in Account Payables figures came in at -$54000.0 (Q4 2024), -$227000.0 (Q3 2024), and -$184000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Scinai Immunotherapeutics | 3.02 Bn | 988.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -54,000.00 |
| Dec 31, 2024 | -54,000.00 |
| Sep 30, 2024 | -227,000.00 |
| Sep 30, 2024 | -227,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Dec 31, 2023 | -206,000.00 |
| Dec 31, 2023 | -206,000.00 |
| Sep 30, 2023 | -104,000.00 |
| Sep 30, 2023 | -104,000.00 |
| Jun 30, 2023 | -660,000.00 |
| Jun 30, 2023 | -660,000.00 |
| Mar 31, 2023 | 629,000.00 |
| Mar 31, 2023 | 629,000.00 |
| Dec 31, 2022 | 146,000.00 |
| Dec 31, 2022 | 146,000.00 |
| Sep 30, 2022 | 116,000.00 |
| Sep 30, 2022 | 116,000.00 |